Anti-Human ANGPTL3 (Evinacumab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Angiopoietin-like protein 3 (ANGPTL3) is a glycoprotein primarily produced in theliver and plays a crucial role in lipid metabolism. It hinders the function of lipoproteinlipase (LPL) and endothelial lipase (EL) which are essential for breaking downtriglycerides and phospholipids. By blocking these enzymes ANGPTL3 increases thelevels of triglycerides LDL cholesterol and HDL cholesterol in the blood. Researchhas shown that mutations in ANGPTL3 that result in reduced function are associatedwith lower lipid levels and a reduced risk of coronary artery disease1-3. The monoclonal antibody REGN 1500, also known as evinacumab, targetsANGPTL3 to treat hypercholesterolemia (HoFH) a rare genetic conditioncharacterized by extremely high cholesterol levels. Evinacumab works by inhibitingANGPTL3, which helps break down fats and leads to a decrease in low-densitylipoprotein cholesterol (LDL-C). Clinical trials have proven that evinacumab canreduce LDL-C levels by around 47% in patients, with HoFH4-7.

≥ 5.0 mg/ml

ANGPTL3 is found primarily in the liver; however, it is also expressed inother tissues, such as adipose tissue and podocytes in the kidney.